Drug intelligence / Profile preview

BHV-6500

Development stage: Preclinical
Lead developer: Biohaven
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

BHV-6500 is a drug candidate being developed by Biohaven Pharmaceuticals. It is an extracellular degrader that leverages Biohaven's MoDE (Molecular Degrader) and TRAP (Targeted Receptor-mediated Autophagy Protein) platforms, which are based on technology licensed from Yale University. The drug is designed to remove specific disease-causing proteins, indicating a targeted protein degradation approach.

Beyond the preview

Go deeper on BHV-6500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHV-6500.

Explore the full profile